COPENHAGEN, Denmark--(BUSINESS WIRE)--Santaris Pharma, the Danish biopharmaceutical company, announced today that the Danish National Advanced Technology Foundation (ATF) has awarded a major program grant of DKK 45m (€6m, $9m) towards the development of a high-throughput drug discovery platform for novel RNA medicines. The project will be based on Santaris Pharma’s proprietary LNA drug chemistry and the screening platform will be developed by a collaborative Research Consortium led by Santaris Pharma and the Biotech Research & Innovation Centre (BRIC) at the University of Copenhagen. Other members of the Consortium are the Nucleic Acid Centre (NAC), University of Southern Denmark, H. Lundbeck A/S, the Danish headquartered pharmaceutical company and RiboTask A/S, the Danish reagents company.
